Core Viewpoint - Q32 Bio is restructuring to focus on the clinical development of bempikibart for alopecia areata, discontinuing the renal basket trial for ADX-097 to conserve resources and extend cash runway to the second half of 2026 [1][2][3] Bempikibart Development Program - Bempikibart has shown encouraging clinical activity in the SIGNAL-AA Phase 2a trial, with significant improvements in the Severity of Alopecia Tool (SALT) score and a notable response rate (SALT-20) through week 36, with continued responses observed up to week 55 [3][4] - The company plans to initiate an open-label extension (OLE) for eligible patients from Part A and begin dosing in Part B of the SIGNAL-AA trial in the first half of 2025, with topline data expected in the first half of 2026 [2][4][6] ADX-097 and Complement Inhibitor Platform - ADX-097 is a Phase 2 tissue-targeted complement inhibitor with potential applications across various conditions, including renal and autoimmune diseases, but its development is being deprioritized in favor of bempikibart [1][7][8] - The restructuring includes evaluating strategic options for the complement inhibitor platform, which includes ADX-097 and other early-stage assets [1][2] Financial Outlook - The company's cash runway is expected to extend into the second half of 2026 due to cost-saving measures, including personnel reductions [1][2]
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata